These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31839918)

  • 1. Occurrence of Takotsubo Cardiomyopathy after Synthetic Cannabinoid Consumption.
    Mohammed D
    Addict Health; 2019 Jul; 11(3):202-206. PubMed ID: 31839918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
    Hopkins CY; Gilchrist BL
    J Emerg Med; 2013 Oct; 45(4):544-6. PubMed ID: 23890687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144.
    Al Fawaz S; Al Deeb M; Huffman JL; Al Kholaif NA; Garlich F; Chuang R
    Am J Case Rep; 2019 Dec; 20():1902-1906. PubMed ID: 31857571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial infarction associated with use of the synthetic cannabinoid K2.
    Mir A; Obafemi A; Young A; Kane C
    Pediatrics; 2011 Dec; 128(6):e1622-7. PubMed ID: 22065271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report.
    Nogi M; Fergusson D; Chiaco JM
    Hawaii J Med Public Health; 2014 Apr; 73(4):115-8. PubMed ID: 24765560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic Thrombocytopenic Purpura Induced by Synthetic Cannabinoid.
    Castaneira G; Rojas K; Galili Y; Field Z; Perez-Perez A; Madruga M; Carlan SJ
    J Addict Med; 2019; 13(3):235-236. PubMed ID: 30531235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will Mary Jane Leave You Heartbroken? Marijuana Use and Risk of Takotsubo Cardiomyopathy.
    Sanchez AM; Sennhauser S; Lozier MR; Purow JM
    Cureus; 2019 Oct; 11(10):e5987. PubMed ID: 31807375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
    Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
    Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist.
    Atwood BK; Huffman J; Straiker A; Mackie K
    Br J Pharmacol; 2010 Jun; 160(3):585-93. PubMed ID: 20100276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue?
    De Luca MA; Fattore L
    Clin Ther; 2018 Sep; 40(9):1457-1466. PubMed ID: 30180974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high.
    Sherpa D; Paudel BM; Subedi BH; Chow RD
    J Community Hosp Intern Med Perspect; 2015; 5(4):27540. PubMed ID: 26333853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
    Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
    Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
    Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driving under the influence of synthetic cannabinoids ("Spice"): a case series.
    Musshoff F; Madea B; Kernbach-Wighton G; Bicker W; Kneisel S; Hutter M; Auwärter V
    Int J Legal Med; 2014 Jan; 128(1):59-64. PubMed ID: 23636569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death.
    Tomiyama K; Funada M
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):17-23. PubMed ID: 24211273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported Use of K2/Spice for Appetite Stimulation: A Case Report.
    Torres C; Espiridion ED
    Cureus; 2020 Apr; 12(4):e7860. PubMed ID: 32483510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.
    McKeever RG; Vearrier D; Jacobs D; LaSala G; Okaneku J; Greenberg MI
    J Med Toxicol; 2015 Mar; 11(1):129-31. PubMed ID: 25154434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.